Tradewinds Capital Management’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Tradewinds Capital Management’s Portfolio BIS Stock Details BIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-9	Closed	-$2K	–	645
2015 Q2	$2K	Buy	+9	New	+$2.23K	﹤0.01%	569

Other funds holding BIS

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

CAM

Chesapeake Asset Management New York $131M AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

Tradewinds Capital Management's BIS Position: Q3 2015 in Review

Tradewinds Capital Management sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q3 2015, closing a stake of 9 shares — an estimated $2K sold.

Tradewinds Capital Management first reported a position in BIS in Q2 2015 and held it in 1 quarter. The position peaked at $2K in Q2 2015. 19 funds tracked by Wall St. Rank hold BIS as of Q3 2015.

Tradewinds Capital Management reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q3 2015 after selling out during the quarter.
Tradewinds Capital Management sold 9 ProShares UltraShort NASDAQ Biotechnology shares in Q3 2015, an estimated $2K.
Tradewinds Capital Management first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q2 2015 and held it in 1 quarter.
Tradewinds Capital Management's ProShares UltraShort NASDAQ Biotechnology position peaked at $2K in Q2 2015.
19 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q3 2015.

Based on Tradewinds Capital Management's 13F filing for Q3 2015, filed 2 Nov 2015.